Drug Type Antibody drug conjugate (ADC) |
Synonyms GB 251, NBT 828, NBT-828 + [1] |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Molecular FormulaC11H22N4O4 |
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N |
CAS Registry159858-33-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2 Positive Breast Cancer | Phase 1 | CN | 13 Apr 2021 | |
Breast Cancer | Phase 1 | CN | - | |
Stomach Cancer | Phase 1 | CN | - |